Latest SEC filings for CRISPR Therapeutics AG (CRSP) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-06-09.
George Simeon (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Behbahani Ali (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Fardis Maria (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Fleming Harold Edward (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Greene John (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
High Katherine A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Mahatme Sandesh (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Morrison Briggs (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Rommel Christian (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Treco Douglas A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
CRISPR Therapeutics AG filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
KASINGER JAMES R. (General Counsel and Secretary) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Patel Naimish (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Prasad Raju (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Patel Naimish, listed as Chief Medical Officer at CRISPR Therapeutics AG, reported an open-market sale of 3,786 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
CRISPR Therapeutics AG filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
CRISPR Therapeutics AG filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
KASINGER JAMES R., listed as General Counsel and Secretary at CRISPR Therapeutics AG, reported an open-market sale of 3,182 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Kulkarni Samarth, listed as Director, Chief Executive Officer at CRISPR Therapeutics AG, reported an open-market sale of 10,020 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Prasad Raju, listed as Chief Financial Officer at CRISPR Therapeutics AG, reported an open-market sale of 3,708 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Executives, directors, and large shareholders must report any purchase or sale of CRSP shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.
Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.
The 8-K is an event-driven filing that CRISPR Therapeutics AG must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.
The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering CRISPR Therapeutics AG's financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.
View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the CRSP stock analysis page.